ARTICLE | Company News
FDA turns down Maxamine
January 19, 2001 8:00 AM UTC
Maxim (MAXM; SSE:MAXM) received a non-approvable letter from the FDA for Ceplene histamine dihydrochloride (formerly Maxamine) as an adjuvant to interleukin-2 (IL-2) to treat advanced metastatic melan...